Literature DB >> 20010337

Atrial fibrillation in congestive heart failure.

Jens Seiler1, William G Stevenson.   

Abstract

Atrial fibrillation (AF) and heart failure (HF) are common and interrelated conditions, each promoting the other, and both associated with increased mortality. HF leads to structural and electrical atrial remodeling, thus creating the basis for the development and perpetuation of AF; and AF may lead to hemodynamic deterioration and the development of tachycardia-mediated cardiomyopathy. Stroke prevention by antithrombotic therapy is crucial in patients with AF and HF. Of the 2 principal therapeutic strategies to treat AF, rate control and rhythm control, neither has been shown to be superior to the other in terms of survival, despite better survival in patients with sinus rhythm compared with those in AF. Antiarrhythmic drug toxicity and poor efficacy are concerns. Catheter ablation of AF can establish sinus rhythm without the risks of antiarrhythmic drug therapy, but has important procedural risks, and data from randomized trials showing a survival benefit of this treatment strategy are still lacking. In intractable cases, ablation of the atrioventricular junction and placement of a permanent pacemaker is a treatment alternative; and biventricular pacing may prevent or reduce the negative consequences of chronic right ventricular pacing.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20010337     DOI: 10.1097/CRD.0b013e3181c21cff

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN: 1061-5377            Impact factor:   2.644


  19 in total

1.  Low-energy multistage atrial defibrillation therapy terminates atrial fibrillation with less energy than a single shock.

Authors:  Wenwen Li; Ajit H Janardhan; Vadim V Fedorov; Qun Sha; Richard B Schuessler; Igor R Efimov
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-10-06

2.  Mortality in patients with atrial fibrillation and common co-morbidities - a cohort study in primary care.

Authors:  Per Wändell; Axel C Carlsson; Martin J Holzmann; Johan Ärnlöv; Jan Sundquist; Kristina Sundquist
Journal:  Ann Med       Date:  2017-11-27       Impact factor: 4.709

3.  Atrial fibrillation and mortality in heart failure: a community study.

Authors:  Alanna M Chamberlain; Margaret M Redfield; Alvaro Alonso; Susan A Weston; Véronique L Roger
Journal:  Circ Heart Fail       Date:  2011-09-15       Impact factor: 8.790

Review 4.  The Relationship Between Atrial Fibrillation and Chronic Kidney Disease : Epidemiologic and Pathophysiologic Considerations for a Dual Epidemic.

Authors:  David D McManus; Jane S Saczynski; Jeanine A Ward; Khushleen Jaggi; Peter Bourrell; Chad Darling; Robert J Goldberg
Journal:  J Atr Fibrillation       Date:  2012-06-15

5.  Effect of cardiovascular drug classes on all-cause mortality among atrial fibrillation patients treated in primary care in Sweden: a cohort study.

Authors:  Per Wändell; Axel C Carlsson; Kristina Sundquist; Sven-Erik Johansson; Jan Sundquist
Journal:  Eur J Clin Pharmacol       Date:  2012-09-19       Impact factor: 2.953

6.  Associations between relevant cardiovascular pharmacotherapies and incident heart failure in patients with atrial fibrillation: a cohort study in primary care.

Authors:  Per Wändell; Axel C Carlsson; Martin J Holzmann; Johan Ärnlöv; Jan Sundquist; Kristina Sundquist
Journal:  J Hypertens       Date:  2018-09       Impact factor: 4.844

7.  The association between relevant co-morbidities and prevalent as well as incident heart failure in patients with atrial fibrillation.

Authors:  Per Wändell; Axel C Carlsson; Martin J Holzmann; Johan Ärnlöv; Jan Sundquist; Kristina Sundquist
Journal:  J Cardiol       Date:  2018-02-01       Impact factor: 3.159

8.  Termination of sustained atrial flutter and fibrillation using low-voltage multiple-shock therapy.

Authors:  Christina M Ambrosi; Crystal M Ripplinger; Igor R Efimov; Vadim V Fedorov
Journal:  Heart Rhythm       Date:  2010-10-19       Impact factor: 6.343

9.  Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study.

Authors:  Agata Bielecka-Dabrowa; Jan Henryk Goch; Jacek Rysz; Marek Maciejewski; Ravi Desai; Wilbert S Aronow; Maciej Banach
Journal:  Lipids Health Dis       Date:  2010-02-23       Impact factor: 3.876

10.  Recent trends in the incidence, treatment, and prognosis of patients with heart failure and atrial fibrillation (the Worcester Heart Failure Study).

Authors:  David D McManus; Jane S Saczynski; Darleen Lessard; Menhel Kinno; Rahul Pidikiti; Nada Esa; Josephine Harrington; Robert J Goldberg
Journal:  Am J Cardiol       Date:  2013-05-15       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.